emendrixAccount

Provision history · CLP

Annex VI · Harmonised classification and labelling for certain hazardous substances

Classification, Labelling and Packaging Regulation · 32008R1272 · every version of this act · on EUR-Lex

26 changes recorded across 26 versions, newest first.

Follow this provision (Atom) · Watch it from CI · Watch this provision

Version in force Modified +13,572 −5,286

Amended by Regulation (EU) 2024/2564 32024R2564 on EUR-Lex

Applies from: no date changed

Not in every listWhat this means

Found in the text, but not every source lists it — the text comparison found this change; the EU's own amendment metadata does not list it. The source that does not name it is the EU's own amendment metadata. Both are shown; neither is overruled.

Explanation, written by a model and checked against the cited text

The entry for trimethyl borate (index 005-005-00-1) has been changed so that, in addition to the flammable liquid classification, it now carries a Repr. 1B classification with hazard statement H360FD, alongside a revised Acute Tox. 4 entry, and its pictograms, labelling codes and hazard statements have been updated accordingly, with a Note 11 reference added.

In the earlier version this same entry showed only the flammable liquid and Acute Tox. 4 classifications with hazard statements H226 and H312, without any reproductive toxicity classification or Note 11 reference.

The remainder of the visible Annex VI text, including the introductory parts and the surrounding table entries, is unchanged between the two versions, and the material beyond the truncation marker in both texts is not part of what can be described here.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

25 entries added, 14 amended, 0 removed.

1 row carries no key and is not compared.

25 entries added

Added entries, Annex VI section 3, table 1
IdentifiersIndex NoChemical nameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATEs Notes
Hazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)
Index No 005-023-00-XCAS 10486-00-7CAS 13517-20-9CAS 37244-98-7EC 234-390-0EC 239-172-9005-023-00-Xperboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]239-172-9 [1] 234-390-0 [2] - [3] - [4]13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4]Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1H360FD H332 H335 H318GHS08 GHS05 GHS07 DgrH360FD H332 H335 H318inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 %11
Index No 005-024-00-5CAS 7632-04-4EC 231-556-4005-024-00-5sodium peroxometaborate231-556-47632-04-4Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1H272 H360FD H331 H302 H335 H318GHS03 GHS08 GHS06 GHS05 DgrH272 H360FD H331 H302 H335 H318inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 %11
Index No 006-104-00-2006-104-00-2multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T——Carc. 1B STOT RE 1H350i H372 (lung)(inhalation)GHS08 DgrH350i H372 (lung)(inhalation)STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 %
Index No 029-026-00-0CAS 7440-50-8EC 231-159-6029-026-00-0copper [specific surface area > 0,67 mm2/mg]231-159-67440-50-8Aquatic Acute 1 Aquatic Chronic 1H400 H410GHS09 WngH410M = 10 M = 1
Index No 047-004-00-9CAS 7440-22-4EC 231-131-3047-004-00-9silver massive: [particle diameter ≥ 1 mm]231-131-37440-22-4Repr. 2 STOT RE 2H361f H373 (nervous system)GHS08 WngH361f H373 (nervous system)
Index No 047-005-00-4CAS 7440-22-4EC 231-131-3047-005-00-4silver powder: [particle diameter > 100 nm < 1 mm]231-131-37440-22-4Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1H361f H373 (nervous system) H400 H410GHS08 GHS09 WngH361f H373 (nervous system) H410M = 10 M = 10
Index No 047-006-00-XCAS 7440-22-4EC 231-131-3047-006-00-Xsilver nano: [particle diameter > 1 nm ≤ 100 nm]231-131-37440-22-4Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1H361f H373 (nervous system) H400 H410GHS08 GHS09 WngH361f H373 (nervous system) H410M = 1000 M = 1000
Index No 603-247-00-8603-247-00-8reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol——Repr. 1BH360DfGHS08 DgrH360Df
Index No 605-042-00-9CAS 1205-17-0CAS 737776-59-9CAS 737776-68-0EC 214-881-6605-042-00-9α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3]214-881-6 [1] - [2] - [3]1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3]Skin Sens. 1BH317GHS07 WngH317
Index No 605-043-00-4CAS 1335-66-6CAS 1423-46-7CAS 1726-47-2CAS 27939-60-2CAS 35145-02-9CAS 36635-35-5CAS 40702-26-9CAS 6754-27-4CAS 67634-07-5CAS 67801-65-4CAS 68039-48-5CAS 68039-49-6CAS 68737-61-1CAS 6975-94-6CAS 71832-78-5EC 215-638-7EC 215-833-7EC 248-742-6EC 252-395-6EC 253-139-6EC 266-810-3EC 267-186-5EC 268-263-6EC 268-264-1EC 272-113-5EC 276-055-1605-043-00-42,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16]268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16]68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16]Skin Sens. 1H317GHS07 WngH317
Index No 606-157-00-7CAS 18402-84-1606-157-00-7(3E)-dec-3-en-2-one—18402-84-1Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2H332 H304 H315 H411GHS07 GHS08 GHS09 DgrH332 H304 H315 H411EUH071inhalation: ATE = 1,5 mg/L (dusts or mists)
Index No 606-158-00-2CAS 119344-86-4EC 438-340-0606-158-00-22-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one438-340-0119344-86-4Repr. 1B Aquatic Acute 1 Aquatic Chronic 1H360Df H400 H410GHS08 GHS09 DgrH360Df H410M = 1 M = 1
Index No 607-770-00-2CAS 26761-45-5EC 247-979-2607-770-00-22,3-epoxypropyl neodecanoate247-979-226761-45-5Muta. 2 Skin Sens. 1AH341 H317GHS08 GHS07 WngH341 H317Skin Sens. 1A; H317: C ≥ 0,001 %
Index No 607-771-00-8CAS 177406-68-7607-771-00-8benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate—177406-68-7Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2H350 H361fd H317 H411GHS08 GHS07 GHS09 DgrH350 H361fd H317 H411
Index No 607-772-00-3CAS 6259-76-3EC 228-408-6607-772-00-3hexyl salicylate228-408-66259-76-3Repr. 2 Skin Sens. 1H361d H317GHS08 GHS07 WngH361d H317
Index No 607-773-00-9CAS 2386-87-0EC 219-207-4607-773-00-97-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate219-207-42386-87-0Muta. 2 STOT RE 2 Skin Sens. 1H341 H373 (nasal cavity) H317GHS08 GHS07 WngH341 H373 (nasal cavity) H317
Index No 607-774-00-4CAS 100556-82-9CAS 17095-24-8EC 241-164-5607-774-00-4tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3]241-164-5 [1] - [2] - [3]17095-24-8 [1] - [2] 100556-82-9 [3]Resp. Sens. 1A Skin Sens. 1H334 H317GHS08 DgrH334 H317
Index No 607-775-00-XCAS 52556-42-0EC 258-004-5607-775-00-XSodium 3-(allyloxy)-2-hydroxypropanesulphonate258-004-552556-42-0Repr. 1B Eye Dam. 1H360F H318GHS08 GHS05 DgrH360F H318
Index No 609-074-00-4CAS 89-61-2EC 201-923-3609-074-00-41,4-dichloro-2-nitrobenzene201-923-389-61-2Carc. 1BH350GHS08 DgrH350
Index No 611-182-00-1CAS 68516-81-4EC 271-183-4611-182-00-12-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol271-183-468516-81-4Skin Sens. 1AH317GHS07 WngH317Skin Sens. 1A; H317: C ≥ 0,001 %
Index No 612-299-00-0CAS 67306-00-7612-299-00-0fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine—67306-00-7Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410GHS08 GHS07 GHS05 GHS09 DgrH361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1330 mg/kg bw M = 1000 M = 10000
Index No 613-350-00-XCAS 95-14-7EC 202-394-1613-350-00-X1H-benzotriazole202-394-195-14-7Aquatic Chronic 2H411GHS09 WngH411
Index No 613-351-00-5CAS 29385-43-1EC 249-596-6613-351-00-5methyl-1H-benzotriazole249-596-629385-43-1Aquatic Chronic 2H411GHS09 WngH411
Index No 616-243-00-6CAS 110-26-9EC 203-750-9616-243-00-6N,N'-methylenediacrylamide203-750-9110-26-9Muta. 1BH340GHS08 DgrH340
Index No 617-024-00-8CAS 3006-82-4EC 221-110-7617-024-00-8tert-butyl 2-ethylperoxyhexanoate221-110-73006-82-4Repr. 1B Skin Sens. 1H360FD H317GHS08 GHS07 DgrH360FD H317

14 entries amended

Amended entries, Annex VI section 3, table 1
IdentifiersVersionIndex NoChemical nameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATEs Notes
Hazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)
Index No 005-005-00-1CAS 121-43-7EC 204-468-9Before005-005-00-1trimethyl borate204-468-9121-43-7Flam. Liq. 3 Acute Tox. 4 *H226 H312GHS02 GHS07 WngH226 H312
After005-005-00-1trimethyl borate204-468-9121-43-7Flam. Liq. 3 Repr. 1B Acute Tox. 4*H226 H360FD H312GHS02 GHS08 GHS07 DgrH226 H360FD H31211
Index No 016-022-00-9CAS 75-08-1EC 200-837-3Before016-022-00-9ethanethiol; ethyl mercaptan200-837-375-08-1Flam. Liq. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1H225 H332 H400 H410GHS02 GHS07 GHS09 DgrH225 H332 H410
After016-022-00-9ethanethiol; ethyl mercaptan200-837-375-08-1Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1H224 H331 H302 H400 H410GHS02 GHS06 GHS09 DgrH224 H331 H302 H410inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw
Index No 029-019-01-XBefore029-019-01-Xcopper flakes (coated with aliphatic acid)——Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1H331 H302 H319 H400 H410GHS06 GHS09 DgrH331 H302 H319 H410inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10
After029-019-01-Xcopper flakes (coated with aliphatic acid)Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1H331 H302 H319 H400 H410GHS06 GHS09 DgrH331 H302 H319 H410inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 1
Index No 601-037-00-0CAS 110-54-3EC 203-777-6Before601-037-00-0n-hexane203-777-6110-54-3Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2H225 H361f *** H304 H373 ** H315 H336 H411GHS02 GHS08 GHS07 GHS09 DgrH225 H361f *** H304 H373 ** H315 H336 H411STOT RE 2; H373: C ≥ 5 %
After601-037-00-0n-hexane203-777-6110-54-3Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT SE 3 STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2H225 H361f*** H304 H336 H372 (nervous system) H315 H411GHS02 GHS08 GHS07 GHS09 DgrH225 H361f*** H304 H336 H372 (nervous system) H315 H411
Index No 604-020-00-6CAS 90-43-7EC 201-993-5Before604-020-00-62-phenylphenol (ISO)biphenyl-2-ol; 2-hydroxybiphenyl;201-993-590-43-7Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1H319 H335 H315 H400GHS07 GHS09 WngH319 H335 H315 H400
After604-020-00-6biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl201-993-590-43-7Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1Aquatic Chronic 1H351 H314 H318 H317 H400H410GHS08 GHS05 GHS07 GHS09 DgrH351 H314 H317 H410M = 1 M = 1
Index No 605-001-00-5CAS 50-00-0EC 200-001-8Before605-001-00-5formaldehyde …%200-001-850-00-0Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1H350 H341 H301 H311 H331 H314 H317GHS08 GHS06 GHS05 DgrH350 H341 H301 H311 H331 H314 H317* Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 %B, D
After605-001-00-5formaldehyde … %200-001-850-00-0Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1AH350 H341 H330 H302 H314 H317GHS08 GHS06 GHS05 DgrH350 H341 H330 H302 H314 H317EUH071inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 %B, D, F
Index No 607-001-00-0CAS 64-18-6EC 200-579-1Before607-001-00-0formic acid … %200-579-164-18-6Skin Corr. 1AH314GHS05 DgrH314Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 %B
After607-001-00-0formic acid … %200-579-164-18-6Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1AEye Dam. 1H226 H290 H331 H302 H314H318GHS02 GHS05 GHS06 DgrH226 H290 H331 H302 H314EUH071inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 %≤ C < 10 %B
Index No 607-043-00-XCAS 1918-00-9EC 217-635-6Before607-043-00-Xdicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid217-635-61918-00-9Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3H302 H318 H412GHS05 GHS07 DgrH302 H318 H412
After607-043-00-Xdicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid217-635-61918-00-9Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 2H332 H302 H335 H336 H318 H400 H411GHS07 GHS05 GHS09 DgrH332 H302 H335 H336 H318 H410inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1500 mg/kg bw M = 1
Index No 607-094-00-8CAS 79-21-0EC 201-186-8Before607-094-00-8peracetic acid . . . %201-186-879-21-0Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1H226 H242 H332 H312 H302 H314 H400GHS02 GHS05 GHS07 GHS09 DgrH226 H242 H332 H312 H302 H314 H400* STOT SE 3; H335: C ≥ 1 %B D
After607-094-00-8peracetic acid … %201-186-879-21-0Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1Aquatic Chronic 1H242 H330 H310 H301 H314 H400H410GHS02 GHS06 GHS05 GHS09 DgrH242 H330 H310 H301 H314 H410EUH071inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 %M = 10 M = 100B, D, T
Index No 607-198-00-3CAS 121-79-9EC 204-498-2Before607-198-00-3propyl 3,4,5-trihydroxybenzoate204-498-2121-79-9Acute Tox. 4 * Skin Sens. 1H302 H317GHS07 WngH302 H317
After607-198-00-3propyl 3,4,5-trihydroxybenzoate204-498-2121-79-9Acute Tox. 4 Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1H302 H317H400 H410GHS07 GHS09 WngH302 H317H410oral: ATE = 1700 mg/kg bw M = 1 M = 1
Index No 607-432-00-4CAS 178961-20-1CAS 87392-12-9Before607-432-00-4S-metolachlor; reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2]-[1] -[2]87392-12-9 [1] 178961-20-1 [2]Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1H317 H400 H410GHS07 GHS09 WngH317 H410
After607-432-00-4S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide]—87392-12-9Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1H351 H317 H400 H410GHS08 GHS07 GHS09 WngH351 H317 H410EUH066M = 10 M = 10
Index No 613-272-00-6CAS 175013-18-0Before613-272-00-6pyraclostrobin (ISO); methyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate——Acute Tox. 3 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1H331 H315 H400 H410GHS06 GHS09 DgrH331 H315 H410M=100
After613-272-00-6pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate—175013-18-0Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410GHS08 GHS06 GHS09 DgrH361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100
Index No 616-127-00-5EC 430-050-2Before616-127-00-5reaction mass of: N, N'-Ethane-1,2-diylbis(decanamide); 12-Hydroxy-N-[2-[1-oxydecyl)amino]ethyl]octadecanamide; N, N'-Ethane-1,2-diylbis(12hydroxyoctadecanamide)430-050-2—Skin Sens. 1 Aquatic Chronic 2H317 H411GHS07 GHS09 WngH317 H411
After616-127-00-5reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2]430-050-2[1] - [2]- [1] - [2]Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1H317 H400 H410GHS07 GHS09 WngH317 H410M = 100 M = 10
Index No 617-008-00-0CAS 94-36-0EC 202-327-6Before617-008-00-0dibenzoyl peroxide; benzoyl peroxide202-327-694-36-0Org. Perox. B Eye Irrit. 2 Skin Sens. 1H241 H319 H317GHS01 GHS02 GHS07 DgrH241 H319 H317
After617-008-00-0dibenzoyl peroxide; benzoyl peroxide202-327-694-36-0Org. Perox. B Eye Irrit. 2 Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1H241 H319 H317H400 H410GHS01 GHS02 GHS07 GHS09 DgrH241 H319 H317H410M = 10 M = 10
Text from EUR-Lex, before and after

Previous version, in force 1 September 2025 02008R1272-20250901 → this version, in force 1 May 2026 02008R1272-20260501

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 466 unchanged lines … Dgr H250 H314 A 005-005-00-1 trimethyl borate 204-468-9 121-43-7 Flam. Liq. 3 Acute Tox. 4 * H226 Repr. 1B Acute Tox. 4* H226 H360FD H312 GHS02 GHS08 GHS07 Wng H226 H312 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Dgr H226 H360FD H312 11 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * … 250 unchanged lines … disodium octaborate tetrahydrate [2] 234-541-0 [1] 234-541-0 [2] 12008-41-2 [1] 12280-03-4 [2] Repr. 1B H360FD GHS08 Dgr H360FD 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Dgr H360FD 005-023-00-X perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] 239-172-9 [1] 234-390-0 [2] - [3] - [4] 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 H360FD H332 H335 H318 GHS08 GHS05 GHS07 Dgr H360FD H332 H335 H318 inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % 11 005-024-00-5 sodium peroxometaborate 231-556-4 7632-04-4 Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H272 H360FD H331 H302 H335 H318 GHS03 GHS08 GHS06 GHS05 Dgr H272 H360FD H331 H302 H335 H318 inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % 11 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Press. Gas Repr. 1A Acute Tox. 3 * … 1,076 unchanged lines … GHS09 Dgr H318 H334 H410 M=100 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 H410 M=100 006-104-00-2 multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T — — Carc. 1B STOT RE 1 H350i H372 (lung)(inhalation) GHS08 Dgr H350i H372 (lung)(inhalation) STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 % 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 Press. Gas Acute Tox. 3 * Skin Corr. 1B … 2,978 unchanged lines … H331 H410 U 016-022-00-9 ethanethiol; ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 2 Acute Tox. 4 * ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H225 H332 Aquatic Chronic 1 H224 H331 H302 H400 H410 GHS02 GHS07 GHS06 GHS09 Dgr H225 H332 H410 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Dgr H224 H331 H302 H410 inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Muta. 2 Acute Tox. 2 * Acute Tox. 3 * … 2,808 unchanged lines … Wng H302 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 M = 1 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 … 79 unchanged lines … H318 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 M = 1 029-026-00-0 copper [specific surface area > 0,67 mm2/mg] 231-159-6 7440-50-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 H260 … 386 unchanged lines … H315 H318 H410 M = 100 M = 100 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * M = 100 047-004-00-9 silver massive: [particle diameter ≥ 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 H361f H373 (nervous system) GHS08 Wng H361f H373 (nervous system) 047-005-00-4 silver powder: [particle diameter > 100 nm < 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 10 M = 10 047-006-00-X silver nano: [particle diameter > 1 nm ≤ 100 nm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 1000 M = 1000 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 … 2,125 unchanged lines … H410 601-037-00-0 n-hexane 203-777-6 110-54-3 Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * STOT SE 3 STOT RE 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 H225 H361f *** H304 H373 ** H361f*** H304 H336 H372 (nervous system) H315 H336 H411 GHS02 GHS08 GHS07 GHS09 Dgr H225 H361f *** H304 H373 ** H315 H361f*** H304 H336 H411 STOT RE 2; H373: C ≥ 5 % 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B H372 (nervous system) H315 H411 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 … 3,592 unchanged lines … H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 H410 M = 1 603-247-00-8 reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol — — Repr. 1B H360Df GHS08 Dgr H360Df 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B H341 … 304 unchanged lines … GHS09 Wng H302 H319 H410 604-020-00-6 2-phenylphenol (ISO)biphenyl-2-ol; 2-hydroxybiphenyl; 201-993-5 90-43-7 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 H319 H335 H315 H400 GHS07 H410 604-020-00-6 biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl 201-993-5 90-43-7 Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H314 H318 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Wng H319 H335 H315 H400 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Dgr H351 H314 H317 H410 M = 1 M = 1 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 H302 … 541 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* M = 10 605-001-00-5 formaldehyde … % 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1 H350 Skin Sens. 1A H350 H341 H301 H311 H331 H330 H302 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H301 H311 H331 H330 H302 H314 H317 * Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 % B, D H317 EUH071 inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % B, D, F 605-002-00-0 1,3,5-trioxan; trioxymethylene 203-812-5 110-88-3 Flam. Sol. 1 Repr. 2 STOT SE 3 H228 … 310 unchanged lines … 31906-04-4 [2] 51414-25-6 [3] Skin Sens. 1A H317 GHS07 Wng H317 605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Dgr H360Fd 605-042-00-9 α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] 214-881-6 [1] - [2] - [3] 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] Skin Sens. 1B H317 GHS07 Wng H317 605-043-00-4 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] Skin Sens. 1 H317 GHS07 Wng H317 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 H225 H319 … 870 unchanged lines … M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 % B Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 606-157-00-7 (3E)-dec-3-en-2-one — 18402-84-1 Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 H332 H304 H315 H411 GHS07 GHS08 GHS09 Dgr H332 H304 H315 H411 EUH071 inhalation: ATE = 1,5 mg/L (dusts or mists) 606-158-00-2 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one 438-340-0 119344-86-4 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360Df H400 H410 GHS08 GHS09 Dgr H360Df H410 M = 1 M = 1 607-001-00-0 formic acid … % 200-579-1 64-18-6 Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H226 H290 H331 H302 H314 H318 GHS02 GHS05 GHS06 Dgr H226 H290 H331 H302 H314 EUH071 inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % B 607-002-00-6 acetic acid … % 200-580-7 64-19-7 Flam. Liq. 3 Skin Corr. 1A H226 H314 GHS02 … 412 unchanged lines … H335 H315 H410 A 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 * 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Chronic 3 H302 Aquatic Acute 1 Aquatic Chronic 2 H332 H302 H335 H336 H318 H412 GHS05 GHS07 Dgr H302 H400 H411 GHS07 GHS05 GHS09 Dgr H332 H302 H335 H336 H318 H412 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] H410 inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1500 mg/kg bw M = 1 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] 233-002-7 [2] 2300-66-5 [1] 10007-85-9 [2] Eye Irrit. 2 Aquatic Chronic 3 H319 … 442 unchanged lines … GHS05 Dgr H225 H314 EUH014 B D 607-094-00-8 peracetic acid . . . % 201-186-8 79-21-0 Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 H226 H242 H332 H312 H302 607-094-00-8 peracetic acid … % 201-186-8 79-21-0 Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 H242 H330 H310 H301 H314 H400 GHS02 H400 H410 GHS02 GHS06 GHS05 GHS07 GHS09 Dgr H226 H242 H332 H312 H302 Dgr H242 H330 H310 H301 H314 H400 * STOT SE 3; H335: C ≥ 1 % B D H410 EUH071 inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 B, D, T 607-095-00-3 maleic acid 203-742-5 110-16-7 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 … 811 unchanged lines … H412 GHS07 Wng H315 H319 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * H317 H410 oral: ATE = 1700 mg/kg bw M = 1 M = 1 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 Wng H302 … 1,428 unchanged lines … GHS09 Dgr H331 H302 H410 607-432-00-4 S-metolachlor; reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2] -[1] -[2] 87392-12-9 [1] 178961-20-1 [2] Skin Sens. 1 H410 607-432-00-4 S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] — 87392-12-9 Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 Aquatic Chronic 1 H351 H317 H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H317 H410 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Wng H351 H317 H410 EUH066 M = 10 M = 10 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 … 1,739 unchanged lines … H410 oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 M = 1000 607-770-00-2 2,3-epoxypropyl neodecanoate 247-979-2 26761-45-5 Muta. 2 Skin Sens. 1A H341 H317 GHS08 GHS07 Wng H341 H317 Skin Sens. 1A; H317: C ≥ 0,001 % 607-771-00-8 benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate — 177406-68-7 Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 H350 H361fd H317 H411 GHS08 GHS07 GHS09 Dgr H350 H361fd H317 H411 607-772-00-3 hexyl salicylate 228-408-6 6259-76-3 Repr. 2 Skin Sens. 1 H361d H317 GHS08 GHS07 Wng H361d H317 607-773-00-9 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate 219-207-4 2386-87-0 Muta. 2 STOT RE 2 Skin Sens. 1 H341 H373 (nasal cavity) H317 GHS08 GHS07 Wng H341 H373 (nasal cavity) H317 607-774-00-4 tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] 241-164-5 [1] - [2] - [3] 17095-24-8 [1] - [2] 100556-82-9 [3] Resp. Sens. 1A Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317 607-775-00-X Sodium 3-(allyloxy)-2-hydroxypropanesulphonate 258-004-5 52556-42-0 Repr. 1B Eye Dam. 1 H360F H318 GHS08 GHS05 Dgr H360F H318 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 1,535 unchanged lines … H302 H317 H412 609-073-00-9 lithium potassium sodium N,N''-bis{6-[7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalene-1,3,6-trisulfonato}-N'-(2-aminoethyl)piperazine 427-850-9 — Skin Sens. 1 H317 GHS07 Wng H317 610-001-00-3 trichloronitromethane; Wng H317 609-074-00-4 1,4-dichloro-2-nitrobenzene 201-923-3 89-61-2 Carc. 1B H350 GHS08 Dgr H350 610-001-00-3 trichloronitromethane; chloropicrin 200-930-9 76-06-2 Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 … 1,021 unchanged lines … H373 (liver) H315 H318 H411 oral: ATE = 136 mg/kg bw 612-001-00-9 mono-methylamine; [1] H411 oral: ATE = 136 mg/kg bw 611-182-00-1 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol 271-183-4 68516-81-4 Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,001 % 612-001-00-9 mono-methylamine; [1] di-methylamine; [2] tri-methylamine [3] 200-820-0 [1] 204-697-4 [2] … 3,599 unchanged lines … H317 GHS08 GHS07 Dgr H360FD H317 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 H317 612-299-00-0 fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine — 67306-00-7 Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410 Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1330 mg/kg bw M = 1000 M = 10000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * … 2,219 unchanged lines … H410 GHS07 GHS09 Wng H317 H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate — — Acute Tox. 3 * H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate — 175013-18-0 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 Aquatic Chronic 1 H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410 GHS06 H410 GHS08 GHS06 GHS09 Dgr H331 Dgr H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410 M=100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B H410 inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 … 732 unchanged lines … Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd 614-001-00-4 nicotine (ISO); H360Fd 613-350-00-X 1H-benzotriazole 202-394-1 95-14-7 Aquatic Chronic 2 H411 GHS09 Wng H411 613-351-00-5 methyl-1H-benzotriazole 249-596-6 29385-43-1 Aquatic Chronic 2 H411 GHS09 Wng H411 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 1,503 unchanged lines … GHS07 Wng H302 H373** H412 616-127-00-5 reaction mass of: N, N'-Ethane-1,2-diylbis(decanamide); 12-Hydroxy-N-[2-[1-oxydecyl)amino]ethyl]octadecanamide; N, N'-Ethane-1,2-diylbis(12hydroxyoctadecanamide) 430-050-2 — Skin Sens. 1 Aquatic Chronic 2 H317 H411 GHS07 H412 616-127-00-5 reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] 430-050-2 [1] - [2] - [1] - [2] Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H411 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * H410 M = 100 M = 10 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * Eye Irrit. 2 H302 H319 GHS07 Wng H302 … 590 unchanged lines … GHS09 Wng H373 (blood system, thyroid) H410 M = 1000 M = 1000 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 M = 1000 616-243-00-6 N,N'-methylenediacrylamide 203-750-9 110-26-9 Muta. 1B H340 GHS08 Dgr H340 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 70 unchanged lines … GHS09 Wng H242 H315 H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B Eye Irrit. 2 Skin Sens. 1 H241 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H241 H319 H317 GHS01 H317 H400 H410 GHS01 GHS02 GHS07 GHS09 Dgr H241 H319 H317 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] H317 H410 M = 10 M = 10 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] 1,1’-dioxybiscyclohexan-1-ol; [2] cyclohexylidene hydroperoxide; [3] cyclohexanone, peroxide [4] 201-091-1 [1] … 139 unchanged lines … H314 H317 H411 617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08 Wng H341 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Wng H341 617-024-00-8 tert-butyl 2-ethylperoxyhexanoate 221-110-7 3006-82-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Dgr H334 647-002-00-3 cellulase 232-734-4 9012-54-8 Resp. Sens. 1 H334 GHS08 Dgr H334 647-003-00-9 cellobiohydrolase, exo- 253-465-9 37329-65-0 Resp. Sens. 1 H334 GHS08 Dgr H334 647-004-00-4 cellulases with the exception of those specified elsewhere in this Annex — — Resp. Sens. 1 H334 GHS08 … 24,737 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61

Version in force Modified

Amended by Regulation (EU) 2024/197 32024R0197 on EUR-Lex

Applies from: no date changed

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2023/1435 32023R1435 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

Several boron entries in Table 3 (boric acid, diboron trioxide, tetraboron disodium heptaoxide hydrate and related salts) now carry a Note 11 reference in the Notes column, which was absent for these entries before.

The entry for tetraboron disodium heptaoxide hydrate and its related salts also gained an added semicolon separating the listed salt names.

The remainder of the text supplied is truncated, so no further differences beyond these can be described.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2024/2865 32024R2865 on EUR-Lex

Applies from: no date changed

Not in every listWhat this means

Found in the text, but not every source lists it — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. The source that does not name it is the amending act's instructions. All are shown; none is overruled.

Explanation, written by a model and checked against the cited text

Section 2 now adds a new dossier component requiring a scientific justification where a harmonised classification and labelling proposal is made for a group of substances, alongside the existing proposal and justification elements.

The justification-for-other-effects paragraph in section 2 now lists additional excluded hazard categories, naming endocrine disruption for human health and the environment, persistent, bioaccumulative and toxic, very persistent and very bioaccumulative, persistent, mobile and toxic, and very persistent and very mobile, alongside the previously named carcinogenicity, mutagenicity, reprotoxicity and respiratory sensitisation.

That paragraph also now refers to the Union level rather than Community level and cites the active-substance exclusion by reference to Regulation (EU) No 1107/2009 and Regulation (EU) No 528/2012 instead of Directive 91/414/EEC and Directive 98/8/EC, while section 3's Table 3 entries shown in both texts are truncated before any further differences can be identified.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2022/692 32022R0692 on EUR-Lex

Applies from: no date changed

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2023/1434 32023R1434 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

A new Note X has been added to the list of notes relating to the identification, classification and labelling of substances in section 1.1.3.1, describing classification based only on the properties of the part of the substance common to all substances in the entry, with the non-common part requiring separate evaluation for possibly more severe or broader classification.

Two new notes, Note 11 and Note 12, have been added to the list of notes relating to the classification and labelling of mixtures in section 1.1.3.2, both addressing when a mixture must be classified as a reproductive toxicant based on summed concentrations of relevant substances.

The corresponding before text in section 1.1.3.1 ends with Note W and the before text in section 1.1.3.2 ends with Note 10, without these additional notes present.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2023/707 32023R0707 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The table of hazard class and category codes in section 1.1.2.1.1 now includes new rows for endocrine disruptor codes for human health (ED HH 1 and ED HH 2) and for the environment (ED ENV 1 and ED ENV 2), and it adds persistence-related codes PBT, vPvB, PMT and vPvM alongside the aspiration and aquatic hazard entries.

The corresponding earlier version of this table in the before text lists only the aspiration hazard and hazardous-to-the-aquatic-environment rows followed directly by the ozone layer row, without any endocrine disruptor or persistence/mobility codes.

Both texts are shown truncated partway through the substance listing table, so any further differences beyond this added set of hazard codes cannot be described here.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2021/849 32021R0849 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

In the visible portion of Section 3's table, several boron entries have been altered: the boric acid entry (005-007-00-2) and the diboron trioxide entry (005-008-00-8) drop the specific-concentration-limit notes and percentage thresholds for Repr. 1B / H360FD that appeared in the earlier text.

Entry 005-011-00-4, previously listed as disodium tetraborate anhydrous with two separate related entries for the decahydrate and pentahydrate forms (005-011-01-1 and 005-011-02-9), is replaced by a single consolidated entry combining tetraboron disodium heptaoxide hydrate, disodium tetraborate anhydrous, orthoboric acid sodium salt, disodium tetraborate decahydrate and disodium tetraborate pentahydrate as five components with corresponding EC and CAS numbers, without the earlier percentage-based concentration limit notes.

Because the provided texts are truncated partway through the table, only these changes within the shown fragment of Section 3 can be described, and any further differences elsewhere in the section cannot be determined from what was given.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2020/1182 32020R1182 on EUR-Lex

Applies from: no date changed

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2021/797 32021R0797 on EUR-Lex · Regulation (EU) 2020/217 32020R0217 on EUR-Lex · Regulation (EU) 2021/1962 32021R1962 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The list of notes on identification, classification and labelling of substances gains two new entries, Note V and Note W, which were not present before.

Note V addresses evaluation of the substance when placed on the market as fibres or particles meeting certain criteria, including consideration of a higher category or additional routes of exposure, while Note W describes a carcinogenic hazard arising from inhalation of respirable dust and states that it does not constitute a classification criterion.

The notes relating to classification and labelling of mixtures also gain a new Note 10 concerning classification as a carcinogen by inhalation for powder mixtures containing titanium dioxide, and the truncated Table 3 material prevents further comparison of section 3 beyond what is shown.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2021/643 32021R0643 on EUR-Lex

Applies from: not readable (the text changed beyond its dates, so no date that moved can be read as the application date) why

dates added to the text: 2008-05-30

Explanation, written by a model and checked against the cited text

The wording of Notes J, K, L, M, N, P, Q and R in section 1.1.3.1 was rephrased from describing classification exemptions that 'need not apply' below stated thresholds to describing the harmonised classification as applying unless the substance is shown to fall below the stated threshold, with classification under Title II to be performed for those hazard classes in that case.

Note R was also expanded to add a cross-reference to Test method A.22 in the Annex to Commission Regulation (EC) No 440/2008, which was not present before.

In section 1.1.3.2, Notes 8 and 9 were changed from stating that the carcinogen or mutagen classification 'need not apply' below the stated formaldehyde concentration to stating that the classification 'shall apply' unless that concentration threshold is shown to be met.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2019/521 32019R0521 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

In Table 1.1 the row for flammable gases now lists the codes Flam. Gas 1A, Flam. Gas 1B, Flam. Gas 2 and Pyr. Gas in place of the earlier Flam. Gas 1 and Flam. Gas 2 codes.

Table 1.1 also gains a new row for desensitised explosives, listing the codes Desen. Expl. 1, Desen. Expl. 2, Desen. Expl. 3 and Desen. Expl. 4, which did not appear in the earlier text.

The text shown is truncated before the rest of the entries in Table 3, so any further differences beyond section 1.1.2.1.1 cannot be described.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2018/1480 32018R1480 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The explanatory note above the Table 3 column headers was changed from a statement about a converted acute toxicity point estimate referencing Annex I Table 3.1.2 to a statement explaining that ATEs for oral and dermal exposure routes are expressed in mg/kg bodyweight.

The table column heading was also altered, splitting the earlier single heading covering specific concentration limits, M-factors and Acute Toxicity Estimates into a heading for specific concentration limits, M-factors and ATEs together with a separate Notes heading.

The remainder of the visible text, including the substance entries themselves, is unchanged between the two versions, and both texts are truncated before any further differences could be observed.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2020/11 32020R0011 on EUR-Lex · Regulation (EU) 2017/542 32017R0542 on EUR-Lex

Applies from: no date changed

Not in every listWhat this means

Found in the text, but not every source lists it — the text comparison found this change; the EU's own amendment metadata does not list it. The source that does not name it is the EU's own amendment metadata. Both are shown; neither is overruled.

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2018/669 32018R0669 on EUR-Lex · Regulation (EU) 2018/1480 32018R1480 on EUR-Lex · Regulation (EU) 2020/217 32020R0217 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The heading of section 1.1.1.4 was renamed from 'International Chemical Identification' to 'Chemical name', though the body text of that section remains the same.

In the Table 3 header, the column previously labelled 'International Chemical Identification' is now labelled 'Chemical name', and the column previously labelled 'Specific Conc. Limits, M-factors and ATE' is now labelled 'Specific Conc. Limits, M-factors', dropping the reference to Acute Toxicity Estimates (ATE).

The visible portion of the entries table otherwise continues with the same substances and codes, and both versions are truncated before any further differences can be observed.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2017/776 32017R0776 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The reference in Note K to the substance identifier changed from "EINECS No" to "Einecs No", and the accompanying sentence dropped the parenthetical "(Table 3.2)" after the precautionary statement codes.

Note P similarly changed "EINECS No" to "Einecs No" and removed the "(Table 3.1)" and "or the S-phrases (2-)23-24-62 (Table 3.2)" wording, leaving only the precautionary statement codes as applying.

Note S and Note U were consolidated so that they now refer to a single "Table 3" instead of separately to Table 3.1 and Table 3.2, and the Part 3 table itself was retitled from "Table 3.1" to "Table 3", with the column heading changed from "Specific Conc. Limits, M-factors" to "Specific Conc. Limits, M-factors and ATE" and a new note on converted acute toxicity point estimates added before the table.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version detected Modified

no amending act named

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The table of hazard class and category codes now includes an additional entry, Skin Corr. 1, listed alongside the existing Skin Corr. 1A, 1B and 1C codes under skin corrosion/irritation.

Note U has been expanded to list four specific codes for gases under pressure (Press. Gas (Comp.), Press. Gas (Liq.), Press. Gas (Ref. Liq.), Press. Gas (Diss.)) and to state that aerosols are not to be classified as gases under pressure, with a cross-reference to Annex I, Part 2, Section 2.3.2.1, Note 2.

Because both texts were truncated within Part 3's classification table before reaching a comparable point, any further differences in that table beyond what is shown cannot be described.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2017/776 32017R0776 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

The introductory text now refers to a single Table 3 rather than distinguishing Table 3.1 and Table 3.2, and references to Community level and Community-level dossiers in the introductory wording have become Union level in the corresponding places.

Section 1.1.2.3 has been retitled to add Acute Toxicity Estimates (ATE) alongside specific concentration limits and M-factors, and its text now describes harmonised ATE values being listed and used together with SCLs, including a reference to the additivity formula in section 3.1.3.6 of Annex I, replacing the prior wording about an asterisk marking specific concentration limits for acute toxicity under Directive 67/548/EEC.

Section 1.1.3.2 gains two additional notes, Note 8 and Note 9, concerning releasable formaldehyde concentrations for carcinogen and mutagen classification respectively, and sections 1.2 through 1.2.4 and Part 3's heading have been reworded to refer to Table 3 instead of Table 3.1, with the note on minimum classification concentration limits under Directive 67/548/EEC changed from present tense to past tense in section 1.2.1.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2016/918 32016R0918 on EUR-Lex · Regulation (EU) 2016/1179 32016R1179 on EUR-Lex

Applies from: no date changed

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version detected Modified

no amending act named

Applies from: no date changed

No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) 2015/1221 32015R1221 on EUR-Lex

Applies from: not readable why

No text foundWhat this means

A source lists it, but there is no text to show — the EU's own amendment metadata found this change; the text comparison finds no difference in the provision's text. Only the EU's own amendment metadata names it, and it carries no text. Both are shown; neither is overruled.

No explanation shipped — the text comparison did not see this change, so it carries no text; another source named the provision, and it is listed where sources differ.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) No 1297/2014 32014R1297 on EUR-Lex · Regulation (EU) No 605/2014 32014R0605 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

Table 1.1 in section 1.1.2.1.1 adds new hazard class and category codes, splitting the former 'Flammable aerosol' row into separate Chemically Unstable Gas categories A and B alongside the Flam. Gas 1 and 2 codes, and replacing the 'Flammable aerosol' entries with a broader 'Aerosol' class containing three categories.

Section 1.1.2.1.2 rewords the sentence describing how letters are added to hazard statement codes, now saying the letters are added to the 3-digit hazard statement code for further differentiations rather than simply to the 3-digit code.

Section 1.2.3 rewrites its description of hazard statements H360 and H361, changing the phrase about fertility and development, altering how replacement of the general hazard statement is described, and adding new text about the consequence of an unmentioned differentiation and a reference to the obligations in Article 4(3), while the Part 3 introductory text and Table 3.1 entries shown remain textually the same apart from the truncation point being reached earlier in the after text.

Cited: Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version detected Modified

no amending act named

Applies from: no date changed

Explanation, written by a model and checked against the cited text

Both versions list the same long Table 3.1 of harmonised classification and labelling entries in Annex VI, but the after text adds further entries after the calcium carbide line, including a new row for thiram (ISO); tetramethylthiuram disulphide, and also adds a Note T marking to the calcium carbide entry that was absent before.

Because both provided texts are truncated before the table concludes, only these additions up to the visible cut-off can be described, and any further differences beyond that point cannot be determined.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) No 487/2013 32013R0487 on EUR-Lex · Regulation (EU) No 517/2013 32013R0517 on EUR-Lex · Regulation (EU) No 944/2013 32013R0944 on EUR-Lex · Regulation (EU) No 618/2012 32012R0618 on EUR-Lex · Regulation (EU) No 758/2013 32013R0758 on EUR-Lex

Applies from: no date changed

Explanation, written by a model and checked against the cited text

In the entry for boric acid (005-007-00-2), the description of the second listed substance was simplified from a longer technical description of crude natural boric acid with a purity qualifier to simply 'boric acid'.

Several entries had their hazard class code for oxidising solids changed from the abbreviation 'Oxid. Sol.' to 'Ox. Sol.' in entries such as 005-017-00-7, 005-017-01-4, 005-019-00-8 and 005-019-01-5.

The text shown is truncated at the same point in both versions, so further differences beyond entry 006-003-00-3 cannot be described.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EU) No 286/2011 32011R0286 on EUR-Lex

Applies from: no date changed

Not in every listWhat this means

Found in the text, but not every source lists it — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. The source that does not name it is the amending act's instructions. All are shown; none is overruled.

Explanation, written by a model and checked against the cited text

The Table 1.1 entries for respiratory and skin sensitisation were widened from a single category label to include sub-categories 1A and 1B, and the ozone-layer hazard class code was changed from a bare class label to include category 1.

Section 1.1.2.3 was expanded to add detailed rules on listing and using M-factors, including how to record separate M-factors for Aquatic Acute 1 and Aquatic Chronic 1 and how a single listed M-factor is to be used by a manufacturer, importer or downstream user, replacing the shorter prior wording on this point.

Section 3 no longer states that Table 3.1 and Table 3.2 are listed in separate Volumes IIIa and IIIb, instead simply describing them as lists of harmonised classification and labelling of hazardous substances.

Cited: Annex VI, v1 · Annex VI, v2

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page

Version in force Modified

Amended by Regulation (EC) No 790/2009 32009R0790 on EUR-Lex

Applies from: no date changed

Not in every listWhat this means

Found in the text, but not every source lists it — the text comparison and the EU's own amendment metadata found this change; the amending act's instructions do not mention it. The source that does not name it is the amending act's instructions. All are shown; none is overruled.

Explanation, written by a model and checked against the cited text

The table of hazardous substance entries in Part 3 has been revised, with some entries such as aluminium lithium hydride and dibutyltin hydrogen borate given different classification, labelling and specific concentration limit details, and new entries such as isobutyllithium and several boron and borate substances added.

The introductory text of sections 1, 1.1 and 1.1.4.4 is substantively unchanged, with only formatting differences such as line breaks and spacing visible between the two versions.

Because both texts are truncated before the full extent of the Table 3.1 changes can be seen, only the differences shown above can be described.

Cited: Annex VI, v2 · Annex VI, v1

v1 is the previous version, v2 this one.

Text from EUR-Lex, on this version's page